Johnson & Johnson (JNJ)
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.
Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a "Buy" for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations. Q3 2024 results showed a 5.2% sales increase but a significant decline in earnings, highlighting mixed performance across segments. The company's strong economic moat, stable margins, and high return on invested capital support its long-term investment appeal.
JNJ ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Johnson & Johnson investment
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson. ("J&J" or the "Company") (NYSE:JNJ).
What To Expect From JNJ Stock In 2025?
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock (up 15%), Johnson & Johnson's stock performance has been muted.
FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab
JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
You will want to build your portfolio the right way if you're going to make money with stocks over the long haul. You wouldn't build your house on a shaky foundation, would you?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
J&J Pauses Sales of Atrial Fibrillation Device, Stock Down
J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.
J&J pauses rollout of heart device in the US to investigate stroke risk
Johnson & Johnson said on Wednesday that it has temporarily paused the rollout of its Varipulse heart device in the United States, citing an abundance of caution as the company investigates four reported stroke events.
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
Johnson & Johnson's stagnant price and bond-like behavior make it an income investment, but a market shift could boost its appeal in 2025. Value stocks, including JNJ, may gain favor as growth stocks' earnings slow and proposed policies boost earnings in other sectors. JNJ's 3.41% dividend yield and attractive forward PE ratio of 13.5 offer potential upside if value stocks regain market attention.
